ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "gout"

  • Abstract Number: 2585 • ACR Convergence 2025

    The effect of prophylactic colchicine use on gene expression in gout

    Austin Wheeler1, Guanqi Lu2, Ana Vazquez3, Jeffrey Edberg4, Angelo Gaffo5, Tate Johnson1, Michael Duryee1, James O'Dell1, Jeff Newcomb1, Michael Pillinger6, Robert Terkeltaub7, Ryan Ferguson8, Mary Brophy8, Tuhina Neogi9, Bryant England1, Ted Mikuls1, Tony Merriman10 and Richard Reynolds4, 1University of Nebraska Medical Center, Omaha, NE, 2Michigan State University, East Lansing, MI, 3Michigan State University, Miami, FL, 4University of Alabama at Birmingham, Birmingham, AL, 5Division of Rheumatology and Clinical Immunology, University of Alabama, Birmingham, AL, USA; Birmingham VA Medical Center, Birmingham, AL, USA, Birmingham, AL, 6New York University Grossman School of Medicine, New York,, NY, 7Retired, San Diego, CA, 8VA Cooperative Studies Program Coordinating Center, Boston, MA, 9Boston University School of Medicine, Boston, MA, 10University of Alabama at Birmingham, Homewood, AL

    Background/Purpose: Colchicine is recommended for the treatment and prophylaxis of gout flares and approved for secondary prevention of ischemic cardiovascular disease (CVD). While its primary…
  • Abstract Number: 1998 • ACR Convergence 2025

    Reduction in Tophi Observed in Patients with Uncontrolled Gout Treated with NASP: Results from Phase 3 DISSOLVE Studies

    Herbert Baraf1, Puja Khanna2, Frédéric Lioté3, Rehan Azeem4, Wesley DeHaan5, Ben Peace6, Hugues Santin-Janin7, Bhavisha Desai8 and Alan Kivitz9, 1The Center for Rheumatology and Bone Research, Rheumatology, Wheaton, Maryland, USA; Division of Rheumatology, The George Washington University, Washington, DC, 2Division of Rheumatology, University of Michigan, Ann Arbor, MI, 3Université Paris Cité-Inserm UMR1132 & Rheumatology Department, GH Paris Saint Joseph & Institut Arthur Vernes, Paris, France, 4Global MACD, Sobi Inc., Waltham, MA, 5Sobi, Inc, Waltham, MA, 6Statistical Science, Sobi, Stockholm, Sweden, 7Sobi, BASEL, Switzerland, 8Sobi, Glastonbury, CT, 9Altoona Center for Clinical Research, Duncansville, PA

    Background/Purpose: Patients (pts) with uncontrolled gout (UG) and tophi experience joint pain, impaired function and poor quality of life (Schlesinger et al. Semin Arthritis Rheum…
  • Abstract Number: 1145 • ACR Convergence 2025

    Numerically Reduced but MSU Crystal-Activated NK Cells Promote Osteoclastogenesis in Gout

    Ki-Jeong Park1, Young-Nan Cho2, Hye-Mi Jin2, Hye-Min Jeong2, Sung-Eun Choi3, Ji-Hyoun Kang1, Dong-Jin Park1, Tae-jong Kim4, Shin-Seok Lee5 and Yong-Wook Park6, 1Chonnam National University Hospital, Gwangju, Republic of Korea, 2Chonnam National University Medical School, Gwangju, Republic of Korea, 3Chonnam National University Medical School & Hospital, Gwangju, Republic of Korea, 4Department of Rheumatology, Chonnam National University Medical School and Hospital, Gwang-Ju, South Korea, 5Chonnam National University Medical School and Hospital, Gwangju, Republic of Korea, 6Department of Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, South Korea

    Background/Purpose: Gout is an inflammatory arthritis characterized by acute attacks, tophi formation, and bone destruction triggered by inflammatory responses to monosodium urate (MSU) crystals. Natural…
  • Abstract Number: 1032 • ACR Convergence 2025

    Exploring the role of the gut microbiome in gout: Prospective analysis of dietary fiber intake and the risk of gout

    Sharan Rai1, Natalie McCormick2, Chio Yokose3, Robert Terkeltaub4, Dylan Dodd5, Lama Nazzal6, Huilin Li6, Qi Sun7 and Hyon K. Choi8, 1Massachusetts General Hospital/Harvard Medical School, Boston, MA, 2Massachusetts General Hospital, Boston, MA, 3Massachusetts General Hospital, Waltham, MA, 4Retired, San Diego, CA, 5Stanford University, Palo Alto, CA, 6NYU Langone, New York, NY, 7Harvard T.H. Chan School of Public Health, Boston, 8MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA

    Background/Purpose: The role of the gut microbiome has been increasingly implicated in the pathogenesis of gout. For instance, gout patients have shown depletions of bacteria…
  • Abstract Number: 2548 • ACR Convergence 2025

    Management of Uncontrolled Gout Among Rheumatologists: Findings from a Medical Chart Audit

    Hyon K. Choi1, Nana Kragh2, Amod Athavale3, Bhavisha Desai4, Amal Gulaid3, Abiola Oladapo5, Brittany Smith3 and Kenneth Saag6, 1MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA, 2Sobi, Kongens Lyngby, Denmark, 3Trinity Life Sciences, Waltham, MA, 4Sobi, Glastonbury, CT, 5Sobi INC, Waltham, MA, 6The University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Uncontrolled gout (UG) is defined by  persistently high sUA levels, despite the use of oral urate lowering treatments (ULT), resulting in gout-related manifestations. Current…
  • Abstract Number: 1997 • ACR Convergence 2025

    Bone health in patients with gout using real-world U.S. data

    Emily Holladay1, Alexis Woods2, Fenglong Xie3, Jingyi Zhang1, Angelo Gaffo4, Jeffrey Curtis5 and Brian Lamoreaux6, 1University of Alabama at Birmingham, Birmingham, AL, 2Amgen, Detroit, MI, 3The University of Alabama at Birmingham, Birmingham, AL, 4Division of Rheumatology and Clinical Immunology, University of Alabama, Birmingham, AL, USA; Birmingham VA Medical Center, Birmingham, AL, USA, Birmingham, AL, 5Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL, 6Amgen, Inc., Deerfield, IL

    Background/Purpose: Patients with gout may be at high risk for developing osteoporosis and fractures, but osteoporosis may be under-recognized and inadequately managed for gout patients.…
  • Abstract Number: 1143 • ACR Convergence 2025

    Gout and Renal Failure-Related Mortality Trends in USA from 1999-2020: Analysis of CDC Wonder Database

    Shiamak Cooper1, Sanjana Thimmannagari2, Ranjini Vengilote2 and Asim Khanfar2, 1Rochester General Hospital, Irondequoit, NY, 2Rochester General Hospital, Rochester, NY

    Background/Purpose: Gout is the most common form of inflammatory arthropathy, with a prevalence ranging from 0.1% to approximately 10% worldwide. Despite a well-established association between…
  • Abstract Number: 1026 • ACR Convergence 2025

    Seasonal Variation in Public Interest in Gout Made More Crystal-Clear: A Longitudinal Infodemiology Study Using Google Trends.

    Naomi Schlesinger1 and Ioannis Androulakis2, 1Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, UT, USA, Salt Lake City, UT, 2Rutgers University, Piscataway, NJ

    Background/Purpose: Understanding public interest in gout, as reflected by online behavior, can offer valuable insights into its perception and management. Infodemiology, which examines the distribution…
  • Abstract Number: 2192 • ACR Convergence 2025

    Survey of Healthcare Providers’ Knowledge and Attitudes Toward the Management of Uncontrolled Gout

    Shilpa Sharan1, Clare Sonntag2, Beth Miller1, Kaitlyn Mayer1 and Nissreen Elfadawy3, 1The HWP Group, Upper Saddle River, NJ, 2The HWP Group, Upper Saddle River, 3University Hospitals, Geauga Medical Center, Chardon, OH

    Background/Purpose: Although uncontrolled gout (UG) is an inflammatory arthritis triggered by crystallization of monosodium urate within joints following hyperuricemia, increasing evidence supports its classification as…
  • Abstract Number: 1995 • ACR Convergence 2025

    The Prevalence of Multimorbidity and Polypharmacy Among US Adults with Gout: A General Population-Based Study

    Chio Yokose1, Natalie McCormick2, Jiaqi Wang2, Sharan Rai3, leo lu4 and Hyon K. Choi5, 1Massachusetts General Hospital, Waltham, MA, 2Massachusetts General Hospital, Boston, 3Massachusetts General Hospital/Harvard Medical School, Boston, MA, 4Arthritis Research Canada, Vancouver, BC, Canada, 5MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA

    Background/Purpose: Gout is an inflammatory-metabolic condition that is associated with a heavy burden of cardiovascular-kidney-metabolic (CKM) comorbidities. Accordingly, multimorbidity and polypharmacy are important considerations which…
  • Abstract Number: 1141 • ACR Convergence 2025

    Modulation of Inflammatory Responses by Dental Pulp Stem Cell Extracellular Vesicles in Monosodium Urate-Stimulated Macrophages

    Sadiq Umar1, Kasey Leung2 and Sriram Ravindran2, 1University of Illinois at Chicago, Chicago, IL, 2University of Illinois, Chicago, IL

    Background/Purpose: Gout is the most prevalent form of inflammatory arthritis, with rising global incidence. It results from the deposition of monosodium urate (MSU) crystals in…
  • Abstract Number: 1012 • ACR Convergence 2025

    Racial and Gender Disparities in Gout Clinical Trials

    Fizza Zulfiqar1, Dania Kaur2, Meaghan Bethea3, Taylor Spencer4, Samhitha Bitla5, Abhinav Vyas6 and Camelia Arsene7, 1Trinity Health Oakland/Wayne State University, Pontiac, MI, 2North Alabama Medical Center, Muscle Shoals, AL, 3Trinity Health Oakland Hopsital, Pontiac, MI, 4Trinity Health Oaklnd Hospital, Pontiac, MI, 5Trinity Health Oakland Hospital, Pontiac, MI, 6Vanderbilt University, Nashvile, TN, 7Trinity Health Oakland Hospital, Pontiac

    Background/Purpose: To develop effective novel treatment strategies for Gout disease that cater to patients from diverse backgrounds, it is crucial that all racial groups, without…
  • Abstract Number: 2014 • ACR Convergence 2025

    Efficacy and Safety of Firsekibart in Acute Gouty Arthritis Patients with eGFR  < 60ml/min/1.73m2:A Post-Hoc Analysis of 24-Week Data

    Yu Xue1, Tianshu Chu2, Jiankang Hu3, Wei Gou4, Ning Zhang5, Juan Li6, Jing Yu7, Rongping Li8, Rongbin Li9, Long Qian10, Xinwang Duan11, Lihua Duan12 and Hejian Zou1, 1Department of Rheumatology,Huashan Hospital, Fudan University, Shanghai, China, shanghai, China (People's Republic), 2Department of Rheumatology, Henan Provincial People's Hospital, Zhengzhou, China, zhengzhou, China (People's Republic), 3Department of Rheumatology, Pingxiang People's Hospital, Pingxiang,China,, Pingxiang, China (People's Republic), 4Department of Rheumatology, Hebei Petro ChinaCentral Hospital, Langfang, China, Langfang, China (People's Republic), 5Department of Rheumatology, Shengjing Hospital of China Medical University, Shenyang, China, Shengjing, China (People's Republic), 6The First Affiliated Hospital of Hainan Medical University, Haikou, China (People's Republic), 7Department of Rheumatology, The FirstAffiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, China, Shenyang, China (People's Republic), 8Department of Rheumatology, The First Affiliated Hospital of GannanMedical University, Ganzhou, China, Ganzhou, China (People's Republic), 9Department ofRheumatology, The First Hospital of Qiqihar, Qiqihar, China, Qiqihar, China (People's Republic), 10Department of Rheumatology, The Second Hopital of Anhui Medical University, Hefei, China, Hefei, China (People's Republic), 11The Second Affiliated Hospital of Nanchang University, Nanchang, China (People's Republic), 12Department of Rheumatology, Jiangxi Provincial People's Hospital, Nanchang, China, Nanchang, China (People's Republic)

    Background/Purpose: Approximately 70% of adults with gout have CKD (Chronic Kidney Disease) ≥stage 3 (i.e estimated glomerular filtration rate (eGFR) < 60ml/min/1.73m2), significantly restricts treatment…
  • Abstract Number: 1993 • ACR Convergence 2025

    Risk of Cardiovascular Conditions, Bone Fractures and Mortality in Patients with Uncontrolled Gout in Comparison to Those with Controlled Gout

    Tingting Zhang1, Christian W. Mende2, Ashraf El-Meanawy3, Michael Pillinger4, Kaiding Zhu5, Bradley Marder6 and Brian Lamoreaux7, 1Amgen, Inc., Thousand Oaks, 2University of California San Diego, San Diego, CA, 3Medical College of Wisconsin, Milwaukee, WI, 4New York University Grossman School of Medicine, New York,, NY, 5Amgen, Inc., San Francisco, CA, 6AMGEN, Inc, Denver, CO, 7Amgen, Inc., Deerfield, IL

    Background/Purpose: Gout may increase the risk of cardiovascular events (CVEs) and bone fractures through urate deposition and chronic inflammation1,2. However, the additional effects of uncontrolled…
  • Abstract Number: 1140 • ACR Convergence 2025

    PGG Suppresses MSU Crystal–Triggered Inflammation and Arachidonic Acid Production in PBMCs

    Sadiq Umar1, Poorna Chandra Rao Yalagala2, Sugasini Dhavamani2 and Sriram Ravindran2, 1University of Illinois at Chicago, Chicago, IL, 2University of Illinois, Chicago, IL

    Background/Purpose: Gout is the most prevalent inflammatory arthritis globally, with rising incidence in both developed and developing regions. It is driven by monosodium urate (MSU)…
  • 1
  • 2
  • 3
  • …
  • 49
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology